Archemix inks two new aptamer deals

Merck KGaA has agreed to take a $29.8 million stake in Archemix as the two drug developers expand their collaboration into aptamer-based therapies for cancer. And Merck will buy up more of Archemix's stock in the event of an IPO. They will also partner on autoimmune and inflammatory programs. "Aptamers have the potential to play a key role in the next generation of drugs in our core therapeutic areas," said Bernhard Kirschbaum, a director of research at Merck Serono. Last week, FierceBiotech named Archemix one of this year's Fierce 15 companies.

- see this release for more
- check out the report from Hemscott

ALSO: Archemix also announced today that it will gain a $6 million upfront payment from Takeda to collaborate on new drug candidates for three disease-associated targets. "Our alliance with Takeda is the sixth major partnership we have formed within the past year and is a major step in the continued validation of aptamer therapeutics," said Errol De Souza, Ph.D., president and CEO, Archemix. Release

Related Articles:
Archemix and Pfizer forge discovery pact. Report
Nuvelo expands collaboration pact with Archemix. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.